CN105142626A - Vsn16的结晶形态 - Google Patents

Vsn16的结晶形态 Download PDF

Info

Publication number
CN105142626A
CN105142626A CN201480013204.7A CN201480013204A CN105142626A CN 105142626 A CN105142626 A CN 105142626A CN 201480013204 A CN201480013204 A CN 201480013204A CN 105142626 A CN105142626 A CN 105142626A
Authority
CN
China
Prior art keywords
crystal habit
compound
disorder
treatment
crystal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480013204.7A
Other languages
English (en)
Chinese (zh)
Inventor
大卫·塞尔伍德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Canbex Therapeutics Ltd
Original Assignee
Canbex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canbex Therapeutics Ltd filed Critical Canbex Therapeutics Ltd
Publication of CN105142626A publication Critical patent/CN105142626A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/68—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/69—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of an acyclic saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201480013204.7A 2013-01-18 2014-01-17 Vsn16的结晶形态 Pending CN105142626A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1300903.0A GB201300903D0 (en) 2013-01-18 2013-01-18 Crystalline Form
GB1300903.0 2013-01-18
PCT/GB2014/050127 WO2014111720A1 (en) 2013-01-18 2014-01-17 Crystalline form of vsn16

Publications (1)

Publication Number Publication Date
CN105142626A true CN105142626A (zh) 2015-12-09

Family

ID=47843537

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480013204.7A Pending CN105142626A (zh) 2013-01-18 2014-01-17 Vsn16的结晶形态

Country Status (9)

Country Link
US (1) US9682924B2 (https=)
EP (1) EP2945619B1 (https=)
JP (1) JP2016505036A (https=)
CN (1) CN105142626A (https=)
CA (1) CA2897524A1 (https=)
GB (1) GB201300903D0 (https=)
NZ (1) NZ630795A (https=)
RU (1) RU2015134560A (https=)
WO (1) WO2014111720A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3256112A1 (en) * 2015-02-13 2017-12-20 Canbex Therapeutics Limited Compounds for treating disorders associated with bk channel modulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0403864D0 (en) * 2004-02-20 2004-03-24 Ucl Ventures Modulator
GB0903956D0 (en) 2009-03-06 2009-04-22 Ucl Business Plc Process

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
朱红军: "《有机化学微型实验》", 31 May 2007 *

Also Published As

Publication number Publication date
WO2014111720A1 (en) 2014-07-24
GB201300903D0 (en) 2013-03-06
EP2945619B1 (en) 2019-05-08
RU2015134560A (ru) 2017-02-28
US20150353476A1 (en) 2015-12-10
US9682924B2 (en) 2017-06-20
CA2897524A1 (en) 2014-07-24
EP2945619A1 (en) 2015-11-25
JP2016505036A (ja) 2016-02-18
NZ630795A (en) 2016-07-29

Similar Documents

Publication Publication Date Title
US20090247532A1 (en) Crystalline polymorph of sitagliptin phosphate and its preparation
TWI682929B (zh) 一種阿片樣物質受體（mor）激動劑的鹽、其富馬酸鹽i晶型及製備方法
WO2012093402A1 (en) Processes for the preparation of n-[2-(7-methoxy-1-naphthyl)ethyl]acetamide
HUE027545T2 (en) Crystalline Form of (R) -7-Chloro-N- (quinuclidin-3-yl) benzo [b] thiophene-2-carboxamide hydrochloride monohydrate
WO2011050742A1 (zh) 阿戈美拉汀的新晶型及其制备方法
US10144708B2 (en) Crystalline arylalkylamine compound and process for producing the same
US20080319075A1 (en) Polymorphic forms of nateglinide
AU2001272872A1 (en) Novel form of (R)-N-(5-methyl-8-(4-methylpiperazin-1-YL)-1,2,3,4-tetrahydro -2-naphthyl)-4-morpholinobenzamide
WO2002008212A1 (en) Novel form of (r)-n-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide
KR20070007196A (ko) 펙소페나딘 히드로클로라이드의 결정형 및 이의 제조 방법
US20050014836A1 (en) Crystalline form of nateglinide
KR102659846B1 (ko) 치환된-퀴녹살린-유형 브리지된-피페리딘 화합물의 다형체 형태
CN105142626A (zh) Vsn16的结晶形态
US11208382B2 (en) Entinostat-containing compound, crystal form of compound thereof, and preparation method therefor and pharmaceutical composition thereof
JP2015508751A (ja) ［（２ｒ，３ｓ，４ｒ，５ｒ）−５−（６−（シクロペンチルアミノ）−９ｈ−プリン−９−イル）−３，４−ジヒドロキシテトラヒドロフラン−２−イル］メチルナイトレートの無水多形体及びその製造方法
EP1467964A1 (en) Polymorphic forms of nateglinide
JP2013531662A (ja) カルシウム模倣化合物の新規多形
US8471032B2 (en) Benzimidazole compound in crystal form and salt thereof
US20040116526A1 (en) Polymorphic forms of nateglinide
US9981912B2 (en) Cocrystal of lorcaserin, preparation methods, pharmaceutical compositions and uses thereof
US20080004313A1 (en) Preparation of crystalline polymorphs of rimonabant hydrochloride
CN104936947A (zh) 氯卡色林盐及其晶体、其制备方法和用途
US20050014949A1 (en) Polymorphic forms of nateglinide
EP1981501A2 (en) Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine
JP2025533955A (ja) （２ｓ，５ｒ）－５－（２－クロロフェニル）－１－（２’－メトキシ－［１，１’－ビフェニル］－４－カルボニル）ピロリジン－２－カルボン酸の多形およびその調製プロセス

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20151209

WD01 Invention patent application deemed withdrawn after publication